| Literature DB >> 35150086 |
Álvaro Casas-Herrero1,2,3, Mikel L Sáez de Asteasu2,3, Iván Antón-Rodrigo4,5, Juan Luis Sánchez-Sánchez6, Manuel Montero-Odasso7,8,9, Itxaso Marín-Epelde1, Fernanda Ramón-Espinoza1, Fabricio Zambom-Ferraresi2,3, Roberto Petidier-Torregrosa10, Jaione Elexpuru-Estomba4, Alejandro Álvarez-Bustos10, Arkaitz Galbete2, Nicolás Martínez-Velilla1,2,3, Mikel Izquierdo2,3.
Abstract
BACKGROUND: Physical exercise is an effective strategy for preserving functional capacity and improving the symptoms of frailty in older adults. In addition to functional gains, exercise is considered to be a cornerstone for enhancing cognitive function in frail older adults with cognitive impairment and dementia. We assessed the effects of the Vivifrail exercise intervention for functional capacity, cognition, and well-being status in community-dwelling older adults.Entities:
Keywords: Falls; Frailty; Functional capacity; Multicomponent exercise programme
Mesh:
Year: 2022 PMID: 35150086 PMCID: PMC8977963 DOI: 10.1002/jcsm.12925
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Figure 1Study flow diagram.
Baseline characteristics of the participants
| Variable | Control group ( | Intervention group ( |
|---|---|---|
| Demographic data | ||
| Age, years | 84.0 (4.8) | 84.2 (4.8) |
| Women, | 69 (69.0%) | 63 (71.6%) |
| Body mass index, kg/m | 27.0 (4.3) | 27.1 (3.6) |
| Education, | ||
| <12 years | 80 (80.0%) | 67 (76.1%) |
| ≥12 years | 20 (20.0%) | 21 (23.9%) |
| Living status, | ||
| Alone | 26 (26.0) | 19 (21.6) |
| Caregivers | 12 (12.0) | 9 (10.2) |
| Family members | 60 (60.0) | 58 (65.9) |
| Others | 2 (2.0) | 2 (2.3) |
| Clinical data | ||
| MCI, | 63 (63.0) | 49 (55.7) |
| Mild dementia, | 37 (37.0) | 38 (43.2) |
| Fried criteria, | ||
| Prefrail (1–2 points) | 64 (64.0) | 57 (64.8) |
| Frail (3–5 points) | 36 (36.0) | 31 (35.2) |
| CIRS score, median (IQR) | 5.0 (5.0) | 7.0 (6.0) |
| MNA score, median (IQR) | 13.0 (3.0) | 13.0 (3.0) |
| 1RM leg press, kg | 49.4 (27.2) | 48.0 (24.1) |
| 5 m GVT, s | 7.8 (2.9) | 8.7 (5.5) |
| Primary endpoint measures | ||
| SPPB scale, score | 7.7 (2.5) | 6.8 (2.7) |
| Secondary endpoint measures | ||
| MOCA, score | 15.4 (5.2) | 15.8 (5.2) |
| MEC Lobo, score | 27.1 (4.5) | 26.4 (5.3) |
| Barthel Index, score | 91.7 (10.2) | 91.1 (9.3) |
| Handgrip, kg | 19.2 (7.7) | 19.6 (6.7) |
| Yesavage GDS, score | 3.4 (2.9) | 3.9 (2.9) |
| QoL (EQ‐VAS), score | 71.4 (18.2) | 70.6 (20.6) |
Data are mean (SD) unless otherwise stated. Significant differences were found between groups for SPPB score and CIRS score (P < 0.05).
CIRS, Cumulative Illness Rating Scale; EQ‐VAS, Visual analog scale of the EuroQol questionnaire; GVT, Gait Velocity Test; IQR, interquartile range; MNA, Mini‐Nutritional Assessment; MCI, Mild Cognitive Impairment; MEC, Minimental Cognitive Exam; MOCA, Montreal Cognitive Assessment; QoL, Quality of Life; SPPB, Short Physical Performance Battery; Yesavage GDS, Yesavage Geriatric Depression Scale; 1RM, one‐repetition maximum.
Figure 2Within‐group SPPB score change distribution for both groups.
Results of study endpoints by group at 1 and 3 months post‐intervention
| Endpoints | Time | Control group | Exercise group | Between‐group difference (95% CI) | p‐value between groups |
|---|---|---|---|---|---|
| Primary Endpoint: Changes in functional capacity | |||||
| SPPB scale (points) | 1 month | −0.17 (−0.54, 0.19) | 0.69 (0.29, 1.09) | 0.86 (0.32, 1.41) | 0.002 |
| 3 months | −0.33 (−0.70, 0.04) | 1.07 (0.63, 1.51) | 1.40 (0.82, 1.98) | <0.001 | |
| Secondary Endpoints: Changes in functional, cognition, muscle function, and mood status | |||||
| Barthel Index (points) | 1 month | 0.18 (−1.80, 2.14) | 1.69 (−0.51, 3.89) | 1.51 (−1.44, 4.46) | 0.319 |
| 3 months | −0.10 (−2.11, 1.99) | 0.99 (−1.40, 3.39) | 1.09 (−2.04, 4.21) | 0.499 | |
| MOCA (points) | 1 month | 0.50 (−0.42, 1.42) | 2.25 (1.08, 3.41) | 1.75 (0.27, 3.24) | 0.340 |
| 3 months | −0.13 (−1.08, 0.82) | 2.05 (0.80, 3.28) | 2.17 (0.61, 3.72) | 0.014 | |
| MEC‐Lobo (points) | 1 month | 0.64 (0.03, 1.26) | 0.75 (0.07, 1.43) | 0.10 (−0.81, 1.02) | 0.826 |
| 3 months | −0.50 (−1.13, 0.13) | 0.63 (−0.09, 1.36) | 1.13 (0.18, 2.10) | 0.023 | |
| Handgrip strength (kg) | 1 month | 0.08 (−0.54, 0.71) | 0.70 (0.00, 1.40) | 0.62 (−0.32, 1.56) | 0.200 |
| 3 months | −0.70 (−1.35, −0.05) | 0.35 (−0.42, 1.12) | 1.05 (0.05, 2.06) | 0.042 | |
| Yesavage GDS (points) | 3 months | 0.61 (0.15, 1.07) | −0.51 (−1.04, 0.02) | −1.12 (−1.82, −0.42) | 0.002 |
| QoL (EQ‐VAS) (score) | 3 months | −0.71 (−4.49, 3.08) | −0.49 (−4.93, 3.96) | 0.22 (−5.62, 6.06) | 0.942 |
Data are expressed as mean (95% CI). All data were derived from linear mixed‐effects model. For each group, data are expressed as change from baseline to 1 month and 3 months post‐intervention, determined by the time coefficients (95% CI) of the model. Between‐group differences were determined with time x group interaction. All the endpoints were adjusted by age, sex, endpoint baseline value, and SPPB baseline value. Additionally, cognitive endpoints (MOCA and MEC‐Lobo) were also adjusted by Yesavage GDS, CIRS baseline value, and years of education. A total of 137 patients (78.0% of patients in the control group and 67.0% in the intervention group) at 1 month post‐intervention and 118 patients (72.0% of patients in the control group and 52.3% in the intervention group) at 3 months post‐intervention reached their functional and muscle function endpoints. Cognitive data correspond to 137 patients (78.0% of patients in the control group and 67.0% in the intervention group) at 1 month post‐intervention and 118 patients (71.0% of patients in the control group and 53.4% in the intervention group) at 3 months post‐intervention.
CIRS, Cumulative Illness Rating Scale; EQ‐VAS, Visual Analog Scale of the EuroQol Questionnaire; MEC, Minimental Cognitive Exam; MOCA, MOCA, Montreal Cognitive Assessment; QoL, Quality of Life; SPPB, Short Physical Performance Battery; Yesavage GDS, Yesavage Geriatric Depression Scale.
Figure 3Changes in the functional categories at baseline, 1 month, and 3 months after intervention according to the Vivifrail classification: Disability (SPPB score 0–3 points), Frailty (4–6 points), Prefrailty (7–9 points), and Robust (10–12 points). P‐value after 1 month = 0.062. P‐value after 3 months ≤ 0.001.
Results of secondary endpoints indicative of adverse events for each group
| Endpoints (3 months) | Control group | Exercise group | Rate ratio (95% CI) |
|
|---|---|---|---|---|
| Falls rate (100 person‐month) | 15.4 (10.6, 21.6) | 20.8 (14.2, 29.3) | 1.25 (0.83, 2.21) | 0.225 |
| Hospital readmission rate (100 person‐month) | 3.28 (1.41, 6.46) | 1.72 (0.35, 5.04) | 0.53 (0.11, 1.92) | 0.358 |
| Visits to emergency department rate (100 person‐month) | 9.76 (6.25, 14.5) | 6.32 (3.15, 11.3) | 0.65 (0.31, 1.31) | 0.234 |
| Mortality, % | 0 | 0 | ||
| Transfer, % | ||||
| Home | 100 | 100 | ||
| Institutionalization | 0 | 0 | ||
| Other | 0 | 0 | ||
Data are expressed as rate (95% CI) unless otherwise indicated.